Physical Destruction Segment to Hold Largest Share of Warts Therapeutics Market During 2021–2028
According to our latest study on “Warts Therapeutics Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Type, Treatment, and End User,” the market is projected to reach US$ 2,314.60 million by 2028 from US$ 1,829.54 million in 2021; it is expected to grow at a CAGR of 3.4% from 2021 to 2028. The report highlights the key factors driving the market growth and prominent players with their developments in the market.
The COVID-19 pandemic has negatively impacted the warts therapeutics market in Africa. In Africa, COVID-19 has threatened the control and progress of major high-burden diseases such as HIV, and other sexually transmitted diseases (STIs). With the continuous spread of COVID-19 in Africa, the limited testing, and decreased access to expert STI clinical further fueling an STI epidemic especially among marginalized populations.
Based on treatment, the warts therapeutics market is segmented into physical destruction, immunomodulation, and chemical destruction. The market for physical destruction is further segmented into cryotherapy, surgical removal, and laser treatment. Moreover, the market for immunomodulation is subsegmented into interferons, retinoids, and zinc. The warts therapeutics market for chemical destruction is further segmented into bleomycin, cantharidin, salicylic acid, and others. The physical destruction segment is the largest shareholder in the market, and it is estimated to register the highest CAGR during the forecast period.
Bausch Health Companies Inc.; Nielsen BioSciences, Inc.; Euro Vital Pharma GmbH, Cipla Inc.; Koninklijke Utermöhlen NV; Novan, Inc.; Scholl's Wellness Company; TEVA PHARMACEUTICAL INDUSTRIES LTD; Verrica Pharmaceuticals Inc.; GlaxoSmithKline plc.; and AIM ImmunoTech Inc are among leading companies operating in the global warts therapeutics market.
The report segments warts therapeutics market as follows:
The warts therapeutics market has been segmented on the bases of type, treatment, and end user. Based on type, the market is segmented into common warts, genital warts, flat warts, and others. Based on treatment, the market is segmented into physical destruction, immunomodulation, and chemical destruction. The market for physical destruction is further segmented into cryotherapy, surgical removal, and laser treatment. Moreover, the market for the immunomodulation is further segmented into interferons, retinoids, and zinc. The warts therapeutics market for chemical destruction is further segmented into bleomycin, cantharidin, salicylic acid, and others. By end user, the warts therapeutics market is sub segmented into hospitals, homecare, specialty clinics, and others.
By Geography
- North America
- Europe
- France
- Germany
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific (APAC)
- China
- India
- Japan
- Australia
- South Korea
- Rest of APAC
- Middle East and Africa (MEA)
- Saudi Arabia
- UAE
- South Africa
- Rest of MEA
- South and Central America (SCAM)
- Brazil
- Argentina
- Rest of SCAM
Contact UsContact Person: Sameer JoshiPhone: +1-646-491-9876Email Id: sales@reportsweb.com
